

Kuittinen T, Rovio P, Luukkaala T, Laurila M, Grénman S, Kallioniemi A et al. **Paclitaxel, carboplatin and 1,25-D3 inhibit proliferation of ovarian cancer cells in vitro.** *Anticancer Research.* 2020 Jun 1;40(6):3129-3138. <https://doi.org/10.2196/10.21873/anticanres.14294>

Kohvakka A, Sattari M, Shcherban A, Annala M, Urbanucci A, Kesseli J et al. **AR and ERG drive the expression of prostate cancer specific long noncoding RNAs.** *Oncogene.* 2020;39:5241–5251. <https://doi.org/10.1038/s41388-020-1365-6>

Lehti M, Valkeinen H, Sipilä S, Perhonen M, Rottensteiner M, Pullinen T et al. **Effects of aerobic and strength training on aerobic capacity, muscle strength, and gene expression of lymphomonocytes in patients with stable CAD.** *American Journal of Translational Research.* 2020;12(8):4582-4593.

Nissinen SI, Roine A, Hokkinen L, Karjalainen M, Venäläinen M, Helminen H et al. **Detection of Pancreatic Cancer by Urine Volatile Organic Compound Analysis.** *Anticancer Research.* 2019 Jan;39(1):73-79. <https://doi.org/10.21873/anticanres.13081>

Nurmi A, Muranen TA, Pelttari LM, Kiiski JI, Heikkinen T, Lehto S et al. **Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.** *International Journal of Cancer.* 2019. <https://doi.org/10.1002/ijc.32309>

Venäläinen MK, Roine AN, Häkkinen MR, Vepsäläinen JJ, Kumpulainen PS, Kiviniemi MS et al. **Altered polyamine profiles in colorectal cancer.** *Anticancer Research.* 2018 Jun 1;38(6):3601-3607. <https://doi.org/10.21873/anticanres.12634>

Vuorinen EM, Rajala NK, Ihalainen TO, Kallioniemi A. **Depletion of nuclear import protein karyopherin alpha 7 (KPNA7) induces mitotic defects and deformation of nuclei in cancer cells.** *BMC Cancer.* 2018 Mar 27;18(1). 325. <https://doi.org/10.1186/s12885-018-4261-5>

Granberg KJ, Annala M, Lehtinen B, Kesseli J, Haapasalo J, Ruusuvoori P et al. **Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas.** *Neuro-Oncology.* 2017 Sep 1;19(9):1206-1216. <https://doi.org/10.1093/neuonc/nox028>

Lehtinen B, Raita A, Kesseli J, Annala M, Nordfors K, Yli-Harja O et al. **Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas.** *BMC Cancer.* 2017 May 3;17(1). 310. <https://doi.org/10.1186/s12885-017-3274-9>

Wu X, Bhattarai A, Korkola P, Pertovaara H, Eskola H, Kellokumpu-Lehtinen PL. **The Association Between Liver and Tumor [¹⁸F]FDG Uptake in Patients with Diffuse Large B Cell Lymphoma During Chemotherapy.** *Molecular Imaging and Biology.* 2017;19(5):787–794. <https://doi.org/10.1007/s11307-017-1044-3>

Kuusela J, Kim J, Räsänen E, Aalto-Setälä K. **The Effects of Pharmacological Compounds on Beat Rate Variations in Human Long QT-Syndrome Cardiomyocytes.** *Stem Cell Reviews and Reports.* 2016;12(6):698–707. <https://doi.org/10.1007/s12015-016-9686-0>

Manzini S, Viiri LE, Marttila S, Aalto-Setälä K. **A Comparative View on Easy to Deploy non-Integrating Methods for Patient-Specific iPSC Production.** *Stem Cell Reviews and Reports.* 2015 Dec 1;11(6):900-908. <https://doi.org/10.1007/s12015-015-9619-3>

Friis S, Kesminiene A, Espina C, Auvinen A, Straif K, Schüz J. **European Code against Cancer 4th Edition: Medical exposures, including hormone therapy, and cancer.** *CANCER EPIDEMIOLOGY.* 2015 Dec 1;39:S107-S119. <https://doi.org/10.1016/j.canep.2015.08.003>

McColl N, Auvinen A, Kesminiene A, Espina C, Erdmann F, de Vries E et al. **European Code against Cancer 4th Edition: Ionising and non-ionising radiation and cancer.** *CANCER EPIDEMIOLOGY.* 2015 Dec 1;39:S93-S100. <https://doi.org/10.1016/j.canep.2015.03.016>

Greinert R, de Vries E, Erdmann F, Espina C, Auvinen A, Kesminiene A et al. **European Code against Cancer 4th Edition: Ultraviolet radiation and cancer.** CANCER EPIDEMIOLOGY. 2015 Dec 1;39:S75-S83. <https://doi.org/10.1016/j.canep.2014.12.014>

Hietanen T, Pitkänen M, Kapanen M, Kellokumpu-Lehtinen PL. **Effects of single and fractionated irradiation on natural killer cell populations: Radiobiological characteristics of viability and cytotoxicity in vitro.** Anticancer Research. 2015 Oct 1;35(10):5193-5200.

Ylipää A, Kivinummi K, Kohvakka A, Annala M, Latonen L, Scaravilli M et al. **Transcriptome sequencing reveals PCAT5 as a Novel ERG-Regulated long Noncoding RNA in prostate cancer.** Cancer Research. 2015 Oct 1;75(19):4026-4031. <https://doi.org/10.1158/0008-5472.CAN-15-0217>

Pashayan N, Pharoah PDP, Schleutker J, Talala K, Tammela TLJ, Mänttinen L et al. **Reducing overdiagnosis by polygenic risk-stratified screening: Findings from the Finnish section of the ERSPC.** British Journal of Cancer. 2015 Sep 29;113(7):1086-1093. <https://doi.org/10.1038/bjc.2015.289>

Umbehre MH, Gurel B, Murtola TJ, Sutcliffe S, Peskoe SB, Tangen CM et al. **Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4 ngml⁻¹, normal DRE and negative for prostate cancer.** PROSTATE CANCER AND PROSTATIC DISEASES. 2015 Sep 14;18(3):264-269. <https://doi.org/10.1038/pcan.2015.19>

Kaapu KJ, Ahti J, Tammela TLJ, Auvinen A, Murtola TJ. **Sotalol, but not digoxin is associated with decreased prostate cancer risk: A population-based case-control study.** International Journal of Cancer. 2015 Sep 1;137(5):1187-1195. <https://doi.org/10.1002/ijc.29470>

Rane JK, Ylipää A, Adamson R, Mann VM, Simms MS, Collins AT et al. **Construction of therapeutically relevant human prostate epithelial fate map by utilising miRNA and mRNA microarray expression data.** British Journal of Cancer. 2015 Aug 11;113(4):611-615. <https://doi.org/10.1038/bjc.2015.262>

Sousa S, Brion R, Lintunen M, Kronqvist P, Sandholm J, Mönkkönen J et al. **Human breast cancer cells educate macrophages toward the M2 activation status.** BREAST CANCER RESEARCH. 2015 Aug 5;17(1): 101. <https://doi.org/10.1186/s13058-015-0621-0>

Kapanen M, Laaksomaa M, Tulijoki T, Kellokumpu-Lehtinen PL, Hyödynmaa S. **Effects of remedies made in patient setup process on residual setup errors and margins in head and neck cancer radiotherapy based on 2D image guidance.** Reports of Practical Oncology and Radiotherapy. 2015 Jul 1;20(4):292-298. <https://doi.org/10.1016/j.rpor.2015.03.002>

Zoni E, Van Der Horst G, Van De Merbel AF, Chen L, Rane JK, Pelger RCM et al. **MIR-25 modulates invasiveness and dissemination of human prostate cancer cells via regulation of α -v and α -6 integrin expression.** Cancer Research. 2015 Jun 1;75(11):2326-2336. <https://doi.org/10.1158/0008-5472.CAN-14-2155>

Thomsen FB, Brasso K, Christensen IJ, Johansson JE, Angelsen A, Tammela TLJ et al. **Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long-term follow-up of the SPCG-6 study.** EUROPEAN JOURNAL OF CANCER. 2015 May 30;51(10):1283-1292. <https://doi.org/10.1016/j.ejca.2015.03.021>

Laitinen VH, Rantapero T, Fischer D, Vuorinen EM, Tammela TLJ, Wahlfors T et al. **Fine-mapping the 2q37 and 17q11.2-q22 loci for novel genes and sequence variants associated with a genetic predisposition to prostate cancer.** International Journal of Cancer. 2015 May 15;136(10):2316-2327. <https://doi.org/10.1002/ijc.29276>

Kilpeläinen TP, Tammela TLJ, Malila N, Hakama M, Santti H, Mänttinen L et al. **The Finnish prostate cancer screening trial: Analyses on the screening failures.** International Journal of Cancer. 2015 May 15;136(10):2437-2443. <https://doi.org/10.1002/ijc.29300>

Saarimäki L, Tammela TL, Mänttinen L, Taari K, Kujala PM, Raitanen J et al. **Family history in the Finnish prostate cancer screening trial.** International Journal of Cancer. 2015 May 1;136(9):2172-2177. <https://doi.org/10.1002/ijc.29243>

Veskimäe K, Staff S, Tabaro F, Nykter M, Isola J, Mäenpää J. **Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies.** *Genes Chromosomes and Cancer*. 2015 May 1;54(5):276-287. <https://doi.org/10.1002/gcc.22241>

Saurus P, Kuusela S, Lehtonen E, Hyvönen ME, Ristola M, Fogarty CL et al. **Podocyte apoptosis is prevented by blocking the Toll-like receptor pathway.** *CELL DEATH AND DISEASE*. 2015 May 1;6(5). e1752. <https://doi.org/10.1038/cddis.2015.125>

Schüz J, Espina C, Villain P, Herrero R, Leon ME, Minozzi S et al. **European code against cancer 4th edition: 12 ways to reduce your cancer risk.** *CANCER EPIDEMIOLOGY*. 2015 Apr 9;39:S1-S10. <https://doi.org/10.1016/j.canep.2015.05.009>

Tuohinen SS, Skyttä T, Virtanen V, Luukkaala T, Kellokumpu-Lehtinen PL, Raatikainen P. **Early effects of adjuvant breast cancer radiotherapy on right ventricular systolic and diastolic function.** *Anticancer Research*. 2015 Apr 1;35(4):2141-2147.

Skyttä T, Tuohinen S, Virtanen V, Raatikainen P, Kellokumpu-Lehtinen PL. **The concurrent use of aromatase inhibitors and radiotherapy induces echocardiographic changes in patients with breast cancer.** *Anticancer Research*. 2015 Mar 1;35(3):1559-1566.

Virman JP, Bono P, Luukkaala T, Sunela K, Kujala P, Kellokumpu-Lehtinen PL. **VEGFR3 and CD31 as prognostic factors in renal cell cancer.** *Anticancer Research*. 2015 Feb 1;35(2):921-927.

Emmert-Streib F, Zhang SD, Hamilton P. **Computational cancer biology: education is a natural key to many locks.** *BMC Cancer*. 2015 Jan 15;15(1). 7. <https://doi.org/10.1186/s12885-014-1002-2>

Heijnsdijk EAM, De Carvalho TMD, Auvinen A, Zappa M, Nelen V, Kwiatkowski M et al. **Cost-effectiveness of prostate cancer screening: A simulation study based on ERSPC data.** *JOURNAL OF THE NATIONAL CANCER INSTITUTE*. 2015 Jan 1;107(1). dju366. <https://doi.org/10.1093/jnci/dju366>

Azaïs H, Moussaron A, Bach SK, Bassil A, Betrouni N, Frochot C et al. **FRα: une cible pour la thérapie photodynamique prophylactique des métastases péritonéales ovariennes?** *BULLETIN DU CANCER*. 2014 Dec 1;101(12):1109-1113. <https://doi.org/10.1684/bdc.2014.1977>

Laaksomaa M, Kapanen M, Skyttä T, Peltola S, Hyödynmaa S, Kellokumpu-Lehtinen PL. **Estimation of optimal matching position for orthogonal kV setup images and minimal setup margins in radiotherapy of whole breast and lymph node areas.** *Reports of Practical Oncology and Radiotherapy*. 2014 Nov 1;19(6):369-375. <https://doi.org/10.1016/j.rpor.2014.05.001>

Virman JP, Soini Y, Kujala P, Luukkaala T, Salminen T, Sunela K et al. **Claudins as prognostic factors for renal cell cancer.** *Anticancer Research*. 2014 Aug 1;34(8):4181-4188.

Carlsson S, Roobol MJ, Schröder FH, Hugosson J, Auvinen A. **RE: Prostate-specific antigen screening trials and prostate cancer deaths: The androgen deprivation connection.** *JOURNAL OF THE NATIONAL CANCER INSTITUTE*. 2014 May 14;106(5). dju079. <https://doi.org/10.1093/jnci/dju079>

Auvinen A, Seppä K, Pasanen K, Kurttio P, Patama T, Pukkala E et al. **Chernobyl fallout and cancer incidence in Finland 1988-2007.** *International Journal of Cancer*. 2014 May 1;134(9):2253-2263. <https://doi.org/10.1002/ijc.28554>

Mäenpää J, Puistola U, Riska H, Sintonen H, Saarni O, Juvonen E et al. **Impact of epoetin-beta on anemia and health-related quality of life in cancer patients: A prospective observational study using the generic 15D instrument.** *Anticancer Research*. 2014 May 1;34(5):2325-2330.

Kristensen H, Haldrup C, Strand S, Mundbjerg K, Mortensen MM, Thorsen K et al. **Hypermethylation of the GABRÉmiR-452miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy.** *Clinical Cancer Research*. 2014 Apr 15;20(8):2169-2181. <https://doi.org/10.1158/1078-0432.CCR-13-2642>

Penttinen H, Rautalin M, Roine R, Jahkola T, Kellokumpu-Lehtinen PL, Huovinen R et al. **Quality of life of recently treated patients with breast cancer.** *Anticancer Research.* 2014 Mar 1;34(3):1201-1206.

Schrecengost RS, Dean JL, Goodwin JF, Schiewer MJ, Urban MW, Stanek TJ et al. **USP22 regulates oncogenic signaling pathways to drive lethal cancer progression.** *Cancer Research.* 2014 Jan 1;74(1):272-286. <https://doi.org/10.1158/0008-5472.CAN-13-1954>

Traylor M, Mäkelä KM, Kilarski LL, Holliday EG, Devan WJ, Nalls MA et al. **A Novel MMP12 Locus Is Associated with Large Artery Atherosclerotic Stroke Using a Genome-Wide Age-at-Onset Informed Approach.** *PLOS GENETICS.* 2014;10(7). e1004469. <https://doi.org/10.1371/journal.pgen.1004469>

Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B et al. **Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel.** *EUROPEAN JOURNAL OF CANCER.* 2014;50(9):1617-1627. <https://doi.org/10.1016/j.ejca.2014.03.010>

Veitonmäki T, Murtola TJ, Määtänen L, Taari K, Stenman UH, Tammela TL et al. **Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial.** *British Journal of Cancer.* 2014;111(7):1421-1431. <https://doi.org/10.1038/bjc.2014.381>

Laurila EM, Kallioniemi A. **The diverse role of miR-31 in regulating cancer associated phenotypes.** *Genes Chromosomes and Cancer.* 2013 Dec;52(12):1103-1113. <https://doi.org/10.1002/gcc.22107>

Khanna A, Kauko O, Böckelman C, Laine A, Schreck I, Partanen JI et al. **Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells.** *Cancer Research.* 2013 Nov 15;73(22):6757-6769. <https://doi.org/10.1158/0008-5472.CAN-13-1002>

Kellokumpu-Lehtinen PL, Tuunanen T, Kautio AL, Lehtinen I, Tanner M. **Bi-weekly paclitaxel and capecitabine as a second- Or third-line treatment for advanced breast cancer: A pilot study.** *Anticancer Research.* 2013 Nov;33(11):4941-4945.

Kurtio P, Seppä K, Pasanen K, Patama T, Auvinen A, Pukkala E et al. **Fallout from the Chernobyl accident and overall cancer incidence in Finland.** *CANCER EPIDEMIOLOGY.* 2013 Oct;37(5):585-592. <https://doi.org/10.1016/j.canep.2013.05.006>

Nurminen R, Lehtonen R, Auvinen A, Tammela TLJ, Wahlfors T, Schleutker J. **Fine mapping of 11q13.5 identifies regions associated with prostate cancer and prostate cancer death.** *EUROPEAN JOURNAL OF CANCER.* 2013 Oct;49(15):3335-3343. <https://doi.org/10.1016/j.ejca.2013.06.006>

Ampuja M, Jokimäki R, Juuti-Uusitalo K, Rodriguez-Martinez A, Alarmo EL, Kallioniemi A. **BMP4 inhibits the proliferation of breast cancer cells and induces an MMP-dependent migratory phenotype in MDA-MB-231 cells in 3D environment.** *BMC Cancer.* 2013 Sep 22;13. 429. <https://doi.org/10.1186/1471-2407-13-429>

Högnäs G, Hämälistö S, Rilla K, Laine JO, Vilkki V, Murumägi A et al. **Aneuploidy facilitates oncogenic transformation via specific genetic alterations, including Twist2 upregulation.** *Carcinogenesis.* 2013 Sep;34(9):2000-2009. <https://doi.org/10.1093/carcin/bgt171>

Rahu K, Hakulinen T, Smalyte G, Stengrevics A, Auvinen A, Inskip PD et al. **Site-specific cancer risk in the Baltic cohort of Chernobyl cleanup workers, 1986-2007.** *EUROPEAN JOURNAL OF CANCER.* 2013 Sep;49(13):2926-2933. <https://doi.org/10.1016/j.ejca.2013.04.014>

Dixit D, Ghildiyal R, Anto NP, Ghosh S, Sharma V, Sen E. **Guggulsterone sensitizes glioblastoma cells to Sonic hedgehog inhibitor SANT-1 induced apoptosis in a Ras/NFκB dependent manner.** *Cancer Letters.* 2013 Aug 19;336(2):347-358. <https://doi.org/10.1016/j.canlet.2013.03.025>

Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen PL et al. **Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.** JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2013 Jul 3;105(13):960-967. <https://doi.org/10.1093/jnci/djt121>

Liu W, Xie CC, Thomas CY, Kim ST, Lindberg J, Egevad L et al. **Genetic markers associated with early cancer-specific mortality following prostatectomy.** Cancer. 2013 Jul 1;119(13):2405-2412. <https://doi.org/10.1002/cncr.27954>

Kellokumpu-Lehtinen P, Tuunanen T, Asola R, Elomaa L, Heikkinen M, Kokko R et al. **Weekly paclitaxel-An effective treatment for advanced breast cancer.** Anticancer Research. 2013 Jun;33(6):2623-2628.

Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L et al. **Prostate cancer mortality in the finnish randomized screening trial.** JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2013 May 15;105(10):719-725. <https://doi.org/10.1093/jnci/djt038>

Elme A, Utriainen M, Kellokumpu-Lehtinen P, Palva T, Luoto R, Nikander R et al. **Obesity and physical inactivity are related to impaired physical health of breast cancer survivors.** Anticancer Research. 2013 Apr;33(4):1595-1602.

Bruchmann A, Roller C, Walther TV, Schäfer G, Lehmusvaara S, Visakorpi T et al. **Bcl-2 associated athanogene 5 (Bag5) is overexpressed in prostate cancer and inhibits ER-stress induced apoptosis.** BMC Cancer. 2013 Mar 1;13. 96. <https://doi.org/10.1186/1471-2407-13-96>

Veitonmäki T, Tammela TLJ, Auvinen A, Murtola TJ. **Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level.** EUROPEAN JOURNAL OF CANCER. 2013 Mar;49(4):938-945. <https://doi.org/10.1016/j.ejca.2012.09.030>

Rauhala HE, Teppo S, Niemelä S, Kallioniemi A. **Silencing of the arp2/3 complex disturbs pancreatic cancer cell migration.** Anticancer Research. 2013 Jan;33(1):45-52.

Rantanen T, Kauttu T, Åkerla J, Honkanen T, Krogerus L, Salo J et al. **CIP2A expression and prognostic role in patients with esophageal adenocarcinoma.** MEDICAL ONCOLOGY. 2013;30(3). 684. <https://doi.org/10.1007/s12032-013-0684-7>

Jayakrishnan R, Mathew A, Uutela A, Auvinen A, Sebastian P. **Multiple approaches and participation rate for a community based smoking cessation intervention trial in rural Kerala, India.** ASIAN PACIFIC JOURNAL OF CANCER PREVENTION. 2013;14(5):2891-2896. <https://doi.org/10.7314/APJCP.2013.14.5.2891>

Jayakrishnan R, Uutela A, Mathew A, Auvinen A, Mathew PS, Sebastian P. **Smoking cessation intervention in Rural Kerala, India: Findings of a randomised controlled trial.** ASIAN PACIFIC JOURNAL OF CANCER PREVENTION. 2013;14(11):6797-6802. <https://doi.org/10.7314/APJCP.2013.14.11.6797>

Pukkala E, Helminen M, Haldorsen T, Hammar N, Kojo K, Linnertsjö A et al. **Cancer incidence among Nordic airline cabin crew.** International Journal of Cancer. 2012 Dec 15;131(12):2886-2897. <https://doi.org/10.1002/ijc.27551>

Wu GHM, Auvinen A, Määttänen L, Tammela TLJ, Stenman UH, Hakama M et al. **Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening.** International Journal of Cancer. 2012 Sep 15;131(6):1367-1375. <https://doi.org/10.1002/ijc.27340>

Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TLJ, Ke C et al. **Sarcopenia during androgen-deprivation therapy for prostate cancer.** Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Sep 10;30(26):3271-3276. <https://doi.org/10.1200/JCO.2011.38.8850>

Saarto T, Penttinen HM, Sievänen H, Kellokumpu-Lehtinen PL, Hakamies-Blomqvist L, Nikander R et al. **Effectiveness of a 12-month exercise program on physical performance and quality of life of breast cancer survivors.** Anticancer Research. 2012 Sep;32(9):3875-3884.

Egerdie RB, Saad F, Smith MR, Tammela TLJ, Heracek J, Sieber P et al. **Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.** PROSTATE CANCER AND PROSTATIC DISEASES. 2012 Sep;15(3):308-312. <https://doi.org/10.1038/pcan.2012.18>

Kellokumpu-Lehtinen PL, Hjälm-Eriksson M, Thellenberg-Karlsson C, Åström L, Franzen L, Marttila T et al. **Toxicity in patients receiving adjuvant docetaxel hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: A preplanned safety report of the SPCG-13 trial.** PROSTATE CANCER AND PROSTATIC DISEASES. 2012 Sep;15(3):303-307. <https://doi.org/10.1038/pcan.2012.13>

Liu W, Lindberg J, Sui G, Luo J, Egevad L, Li T et al. **Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer.** Oncogene. 2012 Aug 30;31(35):3939-3948. <https://doi.org/10.1038/onc.2011.554>

Högnäs G, Tuomi S, Veltel S, Mattila E, Murumägi A, Edgren H et al. **Cytokinesis failure due to derailed integrin traffic induces aneuploidy and oncogenic transformation in vitro and in vivo.** Oncogene. 2012 Aug 2;31(31):3597-3606. <https://doi.org/10.1038/onc.2011.527>

Hervonen P, Tulijoki T, Kellokumpu-Lehtinen P. **No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer.** Anticancer Research. 2012 Aug;32(8):3305-3310.

Inouye M, Ripatti S, Kettunen J, Lyytikäinen LP, Oksala N, Laurila PP et al. **Novel Loci for Metabolic Networks and Multi-Tissue Expression Studies Reveal Genes for Atherosclerosis.** PLOS GENETICS. 2012 Aug;8(8). e1002907. <https://doi.org/10.1371/journal.pgen.1002907>

Martens-Uzunova ES, Jalava SE, Dits NF, Van Leenders GJLH, Møller S, Trapman J et al. **Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer.** Oncogene. 2012 Feb 23;31(8):978-991. <https://doi.org/10.1038/onc.2011.304>

Bryant RJ, Pawlowski T, Catto JWF, Marsden G, Vessella RL, Rhee B et al. **Changes in circulating microRNA levels associated with prostate cancer.** British Journal of Cancer. 2012 Feb 14;106(4):768-774. <https://doi.org/10.1038/bjc.2011.595>

Dixit D, Sharma V, Ghosh S, Mehta VS, Sen E. **Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNF α)-induced apoptosis through SIRT1 inhibition.** CELL DEATH AND DISEASE. 2012 Feb;3(2). e271. <https://doi.org/10.1038/cddis.2012.10>

Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R et al. **Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: Final analysis of the randomized FinXX trial.** JOURNAL OF CLINICAL ONCOLOGY. 2012 Jan 1;30(1):11-18. <https://doi.org/10.1200/JCO.2011.35.4639>

Kilpeläinen TP, Tammela TLJ, Roobol M, Hugosson J, Ciatto S, Nelen V et al. **False-positive screening results in the European randomized study of screening for prostate cancer.** EUROPEAN JOURNAL OF CANCER. 2011 Dec;47(18):2698-2705. <https://doi.org/10.1016/j.ejca.2011.06.055>

Koskinen MJ, Kautio AL, Haanpää ML, Haapasalo HK, Kellokumpu-Lehtinen PL, Saarto T et al. **Intraepidermal nerve fibre density in cancer patients receiving adjuvant chemotherapy.** Anticancer Research. 2011 Dec;31(12):4413-4416.

Haillot O, Fraga A, Maclukiewicz P, Pushkar D, Tammela T, Höfner K et al. **The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study.** PROSTATE CANCER AND PROSTATIC DISEASES. 2011 Dec;14(4):302-306. <https://doi.org/10.1038/pcan.2011.13>

Cropp CD, Simpson CL, Wahlfors T, Ha N, George A, Jones MS et al. **Genome-wide linkage scan for prostate cancer susceptibility in Finland: Evidence for a novel locus on 2q37.3 and confirmation of signal on 17q21-q22.** *International Journal of Cancer*. 2011 Nov 15;129(10):2400-2407. <https://doi.org/10.1002/ijc.25906>

Vihinen PP, Ramadan S, Vuoristo MS, Hernberg M, Tyynelä-Korhonen K, Skyttä T et al. **Circulating levels of VEGFR-1 and VEGFR-2 in patients with metastatic melanoma treated with chemoimmunotherapy alone or combined with bevacizumab.** *MELANOMA RESEARCH*. 2011 Oct;21(5):431-437. <https://doi.org/10.1097/CMR.0b013e32834941d3>

Kemppainen KJ, Tammela TLJ, Auvinen A, Murtola TJ. **The association between antihypertensive drug use and incidence of prostate cancer in Finland: A population-based case-control study.** *Cancer Causes and Control*. 2011 Oct;22(10):1445-1452. <https://doi.org/10.1007/s10552-011-9819-3>

Larjavaara S, Feychting M, Sankila R, Johansen C, Klaeboe L, Schüz J et al. **Incidence trends of vestibular schwannomas in Denmark, Finland, Norway and Sweden in 1987-2007.** *British Journal of Cancer*. 2011 Sep 27;105(7):1069-1075. <https://doi.org/10.1038/bjc.2011.344>

Mattila H, Schindler M, Isotalo J, Ikonen T, Vihinen M, Oja H et al. **NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene.** *BMC Cancer*. 2011 Aug 2;11: 327. <https://doi.org/10.1186/1471-2407-11-327>

Nurminen R, Wahlfors T, Tammela TLJ, Schleutker J. **Identification of an aggressive prostate cancer predisposing variant at 11q13.** *International Journal of Cancer*. 2011 Aug 1;129(3):599-606. <https://doi.org/10.1002/ijc.25754>

Colin P, Estevez JP, Betrouni N, Nevoux P, Puech P, Leroy X et al. **Thérapie photodynamique et carcinomes urothéliaux.** *BULLETIN DU CANCER*. 2011 Jul;98(7):769-778. <https://doi.org/10.1684/bdc.2011.1389>

Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH, Dehm SM. **Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression.** *Cancer Research*. 2011 Mar 15;71(6):2108-2117. <https://doi.org/10.1158/0008-5472.CAN-10-1998>

Latonen L, Moore HM, Bai B, Jäämaa S, Laiho M. **Proteasome inhibitors induce nucleolar aggregation of proteasome target proteins and polyadenylated RNA by altering ubiquitin availability.** *Oncogene*. 2011 Feb 17;30(7):790-805. <https://doi.org/10.1038/onc.2010.469>

Schüz J, Elliott P, Auvinen A, Kromhout H, Poulsen AH, Johansen C et al. **An international prospective cohort study of mobile phone users and health (Cosmos): Design considerations and enrolment.** *CANCER EPIDEMIOLOGY*. 2011 Feb;35(1):37-43. <https://doi.org/10.1016/j.canep.2010.08.001>

Schwartzman J, Mongoue-Tchokote S, Gibbs A, Gao L, Corless CL, Jin J et al. **A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer.** *EPIGENETICS*. 2011;6(10):1248-1256. <https://doi.org/10.4161/epi.6.10.17727>